Health Care • Ophthalmic Goods
$25.24 ▲ +0.63
(+2.56%)
MKT CAP: $1.27B • VOL: 454.7K
52W L $16 52W H $36
STAA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2026-01-02 | FY 2024
FILED 2024-12-27 | FY 2023
FILED 2023-12-29 |
|---|---|---|---|
| Revenue (Total Sales) | $239.4M | $313.9M | $322.4M |
| YoY Revenue Growth % | -23.7% | -2.6% | — |
| Gross Profit | $182.4M | $239.6M | — |
| Gross Margin % | 76.2% | 76.3% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$91.7M | -$12.6M | $28.1M |
| Operating Margin % | -38.3% | -4.0% | 8.7% |
| Net Income (GAAP) | -$80.4M | -$20.2M | $21.3M |
| EBITDA (Normalized) | -$87.1M | $6.1M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$34.2M | $15.7M | $14.6M |
| Capital Expenditures (CapEx) | $5.8M | $23.4M | — |
| Free Cash Flow (FCF) | -$40.0M | -$7.7M | $14.6M |
| FCF Margin % | -16.7% | -2.4% | 4.5% |
| Return on Invested Capital (ROIC %) | -37.9% | -3.9% | — |
| Cash & Short-Term Equivalents | $153.2M | $144.2M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $344.2M | $397.3M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR STAA.